At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 121 enrolled
Drug / intervention
Retifanlimabdrug
Likely dose
Retifanlimab 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)
In Brief
A Phase 2 clinical trial evaluating Retifanlimab for Metastatic Non-small Cell Lung Cancer and 6 related conditions. Completed, enrolled 121 participants across 52 sites in 8 countries.
Detailed Summary
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been established.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer, Unresectable Melanoma, Metastatic Melanoma, Locally Advanced Renal Cell Carcinoma, Metastatic Clear-Cell Renal Cell Carcinoma
CountriesAustria, France, Hungary, Italy, Poland, Romania, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartJan 2019
Primary CompletionApr 2021
Study CompletionJun 2022
TodayJul 2026
First PostedSep 20, 2018
Enrollment StartJan 9, 2019
Primary CompletionApr 15, 2021
Study CompletionJun 28, 2022
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 7.8 years ago
Interventions
Retifanlimabdrug
Retifanlimab administered intravenously at 500 mg every 4 weeks